Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/15/2025

Cefalexin Dosing for Pediatric Patients

Infection-Specific Dosing Recommendations

  • For methicillin-susceptible Staphylococcus aureus (MSSA) infections, the Infectious Diseases Society of America recommends oral therapy with 75-100 mg/kg/day divided into 3 or 4 doses 1, 2
  • For urinary tract infections in infants 29-60 days old, the American Academy of Pediatrics recommends 50-100 mg/kg/day divided into 4 doses as an alternative oral option when transitioning from parenteral therapy 3

Severe Infections

  • For severe infections such as MSSA pneumonia, the Infectious Diseases Society of America recommends 75-100 mg/kg/day divided into 3-4 doses 1, 2
  • Cefalexin is not appropriate for pneumococcal pneumonia, and amoxicillin 90 mg/kg/day is recommended instead by the Infectious Diseases Society of America 1, 2
  • Cefalexin is also not appropriate for infections requiring coverage for β-lactamase-producing organisms or methicillin-resistant Staphylococcus aureus (MRSA) according to the Infectious Diseases Society of America 1, 2

Cefalexin Dosing for Pediatric Patients

Standard Dosing Recommendations

  • For most pediatric infections in children over 1 month of age, the American Academy of Pediatrics recommends cefalexin dosing at 25-100 mg/kg/day divided into 2-4 doses depending on infection severity, with typical dosing being 25-50 mg/kg/day for mild infections and up to 100 mg/kg/day for severe infections 4

Weight-Based Dosing Examples

  • For pediatric patients, the standard dosing guidelines recommend weight-based dosing, and for a 9 kg child with mild infection, a dose of 75 mg every 8 hours is suggested, according to the Clinical Guidelines 5

Critical Clinical Considerations

  • The American Academy of Pediatrics advises that for serious infections requiring broader coverage, cefalexin is inadequate and alternative agents like amoxicillin-clavulanate or cefazolin should be used instead, with a strength of evidence based on clinical guidelines 6, 5